Compounds of Formula (I) or pharmaceutically acceptable salt thereof, a pharmaceutical compositions comprising these compounds, the use of these compounds and compositions in the treatment of diseases in which LRRK-2 kinase is involved.
-
Page/Page column 46; 57; 58
(2018/09/08)
COMPOUNDS
Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for examp
-
Paragraph 44; 45
(2018/09/08)
COMPOUNDS
Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
-
Page/Page column 61
(2018/08/20)
COMPOUNDS
Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
-
Page/Page column 52
(2018/08/30)
COMPOUNDS
The present invention provides novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase a
-
Page/Page column 52; 78
(2018/08/20)
COMPOUNDS
Disclosed are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis(ALS).
The present invention relates to substituted 1,3,8-triazaspiro[4.5]decame-2,4-diones useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
-
Page/Page column 66
(2010/12/31)
CALCIUM CHANNEL ANTAGONISTS
The present invention provides novel calcium channel antagonists, and methods of treating disease sates using the novel antagonists.
-
Page/Page column 33
(2010/11/27)
CALCIUM CHANNEL ANTAGONISTS
The present invention provides novel calcium channel antagonists, and methods of treating disease sates using the novel antagonists.
-
Page/Page column 8
(2010/11/28)
More Articles about upstream products of 66298-49-5